Amid the excitement over the results of the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial (1), the potential mechanisms through which empagliflozin produced a rapid and profound reduction in hospitalization for heart failure and cardiovascular (CV) death in subjects with type 2 diabetes remain entirely unexplained. Importantly, the effects of empagliflozin on objective measures of cardiac structure and function are unknown (2). We report the first systematic analysis of echocardiograms of 10 patients with type 2 diabetes and established CV disease in whom empagliflozin 10 mg/day was initiated as per approved clinical indication, without any other concurrent changes in medications. Transthoracic echocardiograms, performed before and 3 months after initiation of empagliflozin, were analyzed by an experienced cardiac echocardiographer not involved in the clinical care of the patients and blinded to identity of the patients and the study order (pre vs. post). Informed patient consent and ethics approval were obtained.
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Baseline patient characteristics were as follows: 80% were men, age was mean (SD) 67.6 (6.6) years, 40% had a previous myocardial infarction, 90% had undergone vascularization, and estimated glomerular filtration rate was 77. 5 These observations, albeit preliminary, suggest the potential of empagliflozin to favorably promote LV reverse remodeling and improve diastolic function in subjects with type 2 diabetes and established CV disease. The rapid cardiac benefits are consistent with the early separation of the Kaplan-Meier curves for heart failure-associated hospitalization and CV mortality in the EMPA-REG OUTCOME trial (1) . Whether the improvement in diastolic function is secondary to a reduction in LV mass or through another distinct mechanism remains unclear. Although the proportion of EMPA-REG OUTCOME patients with systolic versus diastolic dysfunction is unknown, diastolic dysfunction is present in upward of 60% of subjects with diabetes (3).
The mechanisms through which empagliflozin improves diastolic dysfunction and regresses LV mass require further elucidation. Since the human heart does not express sodium-glucose cotransporter 2 (SGLT2) receptors, it is difficult to reconcile any direct effect of the drug on the myocardium per se. However, it is possible that empagliflozin binds to myocardial receptors or substrates other than SGLT2.
The diuretic and natriuretic hypothesis (2) suggests that SGLT2 inhibitors promote sustained reductions in intravascular volume and enhance sodium excretion thereby favorably affecting myocardial loading conditions; this, coupled with an effect on arterial stiffness (4), may lead to ventricular mass regression. While the magnitude of clinical benefit relative to the small nonsignificant changes in LV volume and blood pressure we observed argues against such as the dominant mechanism, lack of power in this study remains possible. The metabolic/myocardial fuel-supply hypothesis postulates that empagliflozin, through increased ketone body production such as b-hydroxybutarate, may provide an alternative and potentially more efficient source of myocardial adenosine triphosphate (5) . Changes in myocardial substrate utilization can have early and in some cases profound effects on ventricular structure and function, and therefore this tenant requires more evaluation.
In summary, we report salutary shortterm changes in LV mass and diastolic function in subjects with type 2 diabetes and established CV disease after empagliflozin initiation. These data, although preliminary, hypothesis generating, and limited by the small number of patients and lack of a control group, may provide a conceptual and translational framework for the remarkable CV benefits in the EMPA-REG OUTCOME trial and open the door to exploring new potential mechanisms and therapeutic uses of SGLT2 inhibitors.
